A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients

Journal of Psychiatric Research

Volumn 41, Issue 3-4, 2007, Pages 351-359

  Nemeroff, Charles B ^a   Thase, Michael E ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Antidepressants; Fluoxetine; Major depressive disorder; Norepinephrine; Serotonin reuptake inhibitors; Venlafaxine

Indexed keywords

FLUOXETINE; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; AGED; ANXIETY; ARTICLE; BLOOD PRESSURE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; HAMILTON SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; OUTPATIENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SWEATING; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS; TREATMENT OUTCOME;

EID: 33845198891     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2005.07.009     Document Type: Article

References (18)

1. TM. Washington (DC): American Psychiatric Association; 1994.
2. Elkin I., Parloff M.B., Hadley S.W., et al. NIMH Treatment of Depression Collaborative Research Program: background and research plan. Archives of General Psychiatry 42 (1985) 305-316
3. Ellingrod V.L., and Perry P.J. Venlafaxine: a heterocyclic antidepressant. American Journal of Hospital Pharmacy 51 (1994) 3033-3046
4. Entsuah R. ETRANK: a ranking procedure for handling missing data in clinical trials: application to venlafaxine extended-release depression trial. Journal of Biopharmaceutical Statistics 6 (1996) 457-475
5. Entsuah A.R. Randomization procedures for analyzing clinical trial data with treatment related withdrawals. Communications in Statistics: Theory and Method 19 (1990) 3859-3880
6. Holliday S.M., and Benfield P. Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs 49 (1995) 280-294
7. Khan A., Warner H.A., and Brown W.A. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials. Archives of General Psychiatry 57 (2000) 311-317
8. Khan A., Leventhal R.M., Khan S.R., and Brown W.A. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. Journal of Clinical Psychopharmacology 22 (2002) 40-45
9. Kirsch I., Moore T.J., Scoboria A., and Nicholls S.S. The emperor's new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prevention and Treatment 1 (1998) [Article 0002a]
10. Lavori P.W., Dawson R., and Shera D. A multiple imputation strategy for clinical trials with truncation of patient data. Statistics of Medicine 14 (1995) 1913-1925
11. Lenderking W.R., Tennen H., Nackley J.F., et al. The effects of venlafaxine on social activity level in depressed outpatients. Journal of Clinical Psychiatry 60 (1999) 157-163
12. Muth E.A., Haskins J.T., Moyer J.A., Husbands G.E., Nielsen S.T., and Sigg E.B. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochemical Pharmacology 35 (1986) 4493-4497
13. Rudolph R.L., and Feiger A.D. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. Journal of Affective Disorders 56 (1999) 171-181
14. Silverstone P.H., and Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. Journal of Clinical Psychiatry 60 (1999) 22-28
15. Smith D., Dempster C., Glanville J., Freemantle N., and Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. British Journal of Psychiatry 180 (2002) 396-404
16. Thase M.E. Comparing the methods used to compare antidepressants. Psychopharmacological Bulletin 36 Suppl. 1 (2002) 1-17
17. Thase M.E., Entsuah A.R., and Rudolph R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. British Journal of Psychiatry 178 (2001) 234-241
18. Ware Jr. J.E., and Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 30 (1992) 473-483